Use of Empagliflozin to Treat Prediabetes
Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Sean A Newsom, Ph.D.
- Phone Number: (541) 737-1613
- Email: sean.newsom@oregonstate.edu
Study Contact Backup
- Name: Matthew M Robinson, Ph.D.
- Phone Number: (541) 737-1126
- Email: matthew.robinson@oregonstate.edu
Study Locations
-
-
Oregon
-
Corvallis, Oregon, United States, 97331
- Oregon State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI 26-45 kg/m2
- Weight stable (± 10 lbs in previous 3 months)
- Fasting blood glucose <126 mg/dL or HbA1c <6.5% (<48mmol/mol)
Exclusion Criteria:
- Regular moderate-vigorous exercise (≥30 min/session on ≥2 days per week)
- Pregnancy, planning to become pregnant or nursing
- Lidocaine allergy
- Current or recent smoking or nicotine use (≤ 1-year abstention)
- Medications including glucose lowering medications and supplements (SGLT2 inhibitors, GLP1 agonists, sulfonylurea, insulin, TZDs); mono-amine oxidase inhibitors; beta-blockers; diuretics
- Major metabolic or cardiovascular conditions (e.g., type 1 diabetes, Crohn's disease, untreated hypo- or hyperthyroid, cancer, coronary artery disease, tachycardia, prior bariatric surgery, peripheral vascular disease, liver diseases (e.g., cirrhosis)
- Diagnosed type 2 diabetes. In absence of diagnosis, two separate samples with test results of fasting blood glucose ≥126 mg/dL or HbA1c ≥6.5% (48 mmol/mol).
- Contraindications/precautions for empagliflozin (impaired renal function (EGR<60), history of: empagliflozin hypersensitivity, ketoacidosis, hypotension, recurring urinary tract or genital mycotic infections, amputation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Empagliflozin
Participants will be provided 10-25mg empagliflozin per day for 13 weeks.
|
Participants will take 10mg empagliflozin per day for 2 weeks.
Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
Other Names:
|
|
Placebo Comparator: Multivitamin-Placebo
Participants will be provided 1 multivitamin-placebo per day for 13 weeks.
|
Participants will take 1 multivitamin per day for 13 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin-stimulated glucose disposal
Time Frame: Insulin-stimulated glucose disposal is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
The glucose infusion rate to maintain glycemia during insulin clamp, using plasma enrichment of glucose isotope tracer to determine changes in rates of insulin-stimulated glucose disposal
|
Insulin-stimulated glucose disposal is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oral glucose tolerance
Time Frame: Oral glucose tolerance is measured before the start of the intervention (baseline) and during week 12 of the intervention.
|
The change in blood glucose concentration in response to a 75g glucose beverage
|
Oral glucose tolerance is measured before the start of the intervention (baseline) and during week 12 of the intervention.
|
|
Fasting plasma glucose concentration
Time Frame: Fasting plasma glucose is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
The change in fasting plasma glucose concentration
|
Fasting plasma glucose is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
|
Whole-body fat oxidation
Time Frame: Whole-body fat oxidation is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Indirect calorimetry will be used to determine the change in whole-body rate of fat oxidation during basal and insulin-stimulated conditions
|
Whole-body fat oxidation is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
|
Skeletal muscle insulin signaling
Time Frame: Skeletal muscle insulin signaling is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Immunoblotting to determine the change in activation of insulin signaling proteins in skeletal muscle collected at basal and during insulin-stimulated conditions
|
Skeletal muscle insulin signaling is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
|
Skeletal muscle lipids
Time Frame: Skeletal muscle lipids are measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Mass spectrometry lipidomic analysis of skeletal muscle to determine changes in muscle lipid content
|
Skeletal muscle lipids are measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
|
Skeletal muscle mitochondrial respiratory function
Time Frame: Skeletal muscle mitochondrial respiratory function is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Changes in skeletal muscle mitochondrial respiratory capacity measured using high-resolution respirometry
|
Skeletal muscle mitochondrial respiratory function is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
|
Skeletal muscle energetic stress
Time Frame: Skeletal muscle energetic stress is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Immunoblotting to determine changes in activation of AMPK and related signaling proteins pathways
|
Skeletal muscle energetic stress is measured before the start of the intervention (baseline) and during week 13 of the intervention.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sean A Newsom, Ph.D., Oregon State University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Overweight
- Obesity
- Prediabetic State
- Sodium-Glucose Transporter 2 Inhibitors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hypoglycemic Agents
- empagliflozin
Other Study ID Numbers
Other Study ID Numbers
- OregonSU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.